about
Spread of artemisinin resistance in Plasmodium falciparum malariaChanges in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deploymentArtemisinin Resistance in Plasmodium falciparum MalariaEmergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal studyGenetic architecture of artemisinin-resistant Plasmodium falciparumAn open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in AsiaPyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trialMalaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational studyDefining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approachReply to Meshnick and Hastings et alLongitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistanceAuditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand.Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria.Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trialSpiroindolone KAE609 for falciparum and vivax malaria.Effect of early detection and treatment on malaria related maternal mortality on the north-western border of Thailand 1986-2010.Malaria in the post-partum period; a prospective cohort studyMethotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax.Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivaxChloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand.Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast AsiaPharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria.Pooled sequencing and rare variant association tests for identifying the determinants of emerging drug resistance in malaria parasitesPharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.A major genome region underlying artemisinin resistance in malariaArtesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects.Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation.Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trialPopulation genetic correlates of declining transmission in a human pathogenGenetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia.Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria.The role of point-of-care tests in antibiotic stewardship for urinary tract infections in a resource-limited setting on the Thailand-Myanmar borderGenetic evaluation of the performance of malaria parasite clearance rate metrics.Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors.Effective and cheap removal of leukocytes and platelets from Plasmodium vivax infected blood.Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives.
P50
Q21032481-141CFFE8-3ABF-4295-82FB-F360A18B55E0Q21032481-9E9CB020-5959-4C31-8599-816E44118ECDQ21090072-C6445103-65B5-414E-A772-8ADE2BF76077Q22061852-3912C22B-7663-4A4C-B37E-CF3595689021Q24598695-959E8695-78ED-4364-A5E0-EBF976DF3C68Q28030935-A5061023-A6B9-48E6-B8BF-E47CE86B3596Q28474978-BDBEC07D-63A8-4678-B561-C38AC75CC656Q28476754-CFBC9B12-C9B1-48AC-A015-A5F50057BA05Q28487636-F0917290-F8A2-4089-9974-B553FC4F2563Q28546794-99D6190B-34BA-49D8-ACA8-D464ABBB5FFDQ28595897-DD718A52-2CD9-47EC-8FED-08E5928FA565Q30044965-DA9251E7-3AA7-4CDC-833A-0E53FF1043A9Q30492414-5882B131-EB93-4ECE-8690-E190C291CFF0Q31153944-0B7641A1-8867-4855-88AD-DE71B35C4365Q33435505-91C94DFC-6676-4A98-B1ED-064A96E6C1B4Q34049080-0F8C9778-7F30-462B-9C11-6D4B6447E6ABQ34085717-5B583751-E528-46B2-A54C-191C6DC68CBBQ34344807-33C35427-0429-403B-A44B-B2F7C41F7BFAQ34629394-32384BFC-35EE-4089-B04B-F06FD302F34BQ34763470-178DC220-A189-4165-9FFA-227F80F06873Q34772862-12AF76F4-9C2C-4252-815D-480C86ECBF61Q35038618-87E35B44-A7A8-4BC2-AFF1-56730D4DA433Q35102586-D3C38EB2-49BE-4686-A0EA-0088EC1BBD70Q35191473-C355684E-4D67-4C24-ADD3-707DB6F305E1Q35232346-E180E85B-62A9-4DAE-9474-60DA251D470FQ35598379-F85C5C53-3E6D-4459-A9C5-5EB7D00243C7Q35806356-05E472F2-8414-4A25-973B-71D9429125C8Q35867343-7D390C57-5FC7-4EA6-A5DC-12F46E494E99Q35969854-DF740145-D77A-480D-BD20-2B4FECC8E667Q36017416-EAC18382-71B6-467E-86B9-CE78A9B7A85CQ36125445-BC5FF8A9-29B3-497B-A64F-C9561F12AE21Q36272772-D13EDC83-E76C-48D4-979C-0C4BE0220324Q36427654-6FB464EF-8843-4DD2-8330-4D034B4F6E20Q36510939-1A515D22-8B73-41ED-9661-101E103D942BQ36512312-0CEE7089-C7CD-4413-931C-77995388C36DQ36584916-C23BC032-AC2E-4115-9273-F6C55EE4D271Q36592840-81F2900C-6BE8-4198-9B97-7AE93D8EA473Q36936359-B6C56FC0-30A5-402C-877E-30581F9FE0D8Q37200509-01E54598-8A81-418F-A871-AF54D7F16990Q37223637-CB8F5813-4440-4911-9341-89B3A11C7F4B
P50
description
Myanmarese medical researcher
@en
medisch onderzoeker uit Myanmar
@nl
հետազոտող
@hy
name
Aung Pyae Phyo
@ast
Aung Pyae Phyo
@en
Aung Pyae Phyo
@es
Aung Pyae Phyo
@fr
Aung Pyae Phyo
@nl
Aung Pyae Phyo
@sl
type
label
Aung Pyae Phyo
@ast
Aung Pyae Phyo
@en
Aung Pyae Phyo
@es
Aung Pyae Phyo
@fr
Aung Pyae Phyo
@nl
Aung Pyae Phyo
@sl
prefLabel
Aung Pyae Phyo
@ast
Aung Pyae Phyo
@en
Aung Pyae Phyo
@es
Aung Pyae Phyo
@fr
Aung Pyae Phyo
@nl
Aung Pyae Phyo
@sl
P108
P1153
25723682300
57191244093
P21
P27
P31
P496
0000-0002-0383-9624